sEH inhibitors were shown to reduce hypertension and endothelial damage in angiotensin II-dependent models (Imig et al., 2002; Gao et al., 2011) and to prevent cardiac dysfunction and remodelling in experimental heart failure (Merabet et al., 2012). This evidence concerns the gene EPHX2 and hypertensive disorder.